The pharmacokinetics of factor VIII and factor IX: Methodology, pitfalls and applications

Haemophilia

Volumn 3, Issue 1, 1997, Pages 1-8

  Bjorkman S ^a   Carlsson, M ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Comparative studies; Dosing; Factor IX; Factor VIII; Methodological aspects; Pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

BLOOD SAMPLING; DRUG ELIMINATION; DRUG HALF LIFE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031028921     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1997.00074.x     Document Type: Review

References (58)

1. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc., 1982; 409-17.
2. Björkman S, Carlsson M, Berntorp E. Pharmacokinetics of Factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 46: 325-32.
3. Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity Factor IX concentrates. Thrombos Haemostas 1993; 70: 768-73.
4. Hoag MS, Johnson FF, Robinson JA, Aggeler PM. Treatment of hemophilia B with a new clotting-factor concentrate. New Eng J Med 1969; 280: 581-6.
5. Zauber NP, Levin J. Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP). Medicine 1977; 56: 213-24.
6. 125iodine-labeled factor VIII in normals and patients with classic hemophilia. J Clin Invest 1978; 62: 223-34.
7. Allain JP, Verroust F, Soulier JP. In vitro and in vivo characterization of factor VIII preparations. Vox Sang 1980; 38: 68-80.
8. McLellan DS, Pelly C, McLellan HG, Jones P, Aronstam A. The in vivo survival characteristics of factor VIII procoagulant antigen (VIII:C Ag) in haemophilia A subjects. Thromb Res 1982; 25: 33-9.
9. Kjellman H. Calculations of Factor VIII in vivo recovery and half-life. Scand J Haematol 1984; 33 (Suppl. 40): 165-74.
10. Allain JP. Principles of in vivo recovery and survival studies. Scand J Haematol 1984; 33 (Suppl. 41): 123-30.
11. Matucci M, Messori A, Donati-Cori G, et al. Kinetic evaluation of four Factor VIII concentrates by model-independent methods. Scand J Haematol 1985; 34: 22-8.
12. Hellstern P, Kiehl R, Miyashita C, et al. Factor VIII:C (FVIII:C) recovery and half-life after infusion of steam-treated high purity Factor VIII concentrate in severe hemophilia A - comparison of one-stage assay, two-stage assay and a chromogenic substrate assay. Thromb Haemostas 1986; 56: 353-9.
13. Messori A, Longo G, Matucci M, Morfini M, Rossi Ferrini PL. Clinical pharmacokinetics of Factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987; 13: 365-80.
14. Longo G, Cinotti S, Filimberti E, et al. Single-dose pharmacokinetics of Factor IX evaluated by model-independent methods. Eur J Haematol 1987; 39: 426-33.
15. Köhler M, Seifried E, Hellstern P, et al. In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. Blut 1988; 57: 341-5.
16. Rousell RH, Kasper CK, Schwartz RS. The pharmacology of a new pasteurized antihemophilic factor concentrate derived from human blood plasma. Transfusion 1989; 29: 208-12.
17. Morfini M, Longo G, Cinotti S, et al. Comparative single-dose pharmacokinetic study of Alphanine vs. Profilnine (abstract). Thromb Haemostas 1991; 65: 1362.
18. Harrison JFM, Bloom AL, Abildgaard CF. The pharmacokinetics of recombinant factor VIII. Semin Hematol 1991; 28 (Suppl. 1): 29-35.
19. Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-75.
20. Goldsmith JC, Kasper CK, Blatt PM, et al. Coagulation factor IX. Successful surgical experience with a purified factor IX concentrate. Am J Hematol 1992; 40: 210-15.
21. Björkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of Factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmakokinet 1992; 22: 385-95.
22. Thomas DP, Hampton KK, Dasani H, et al. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haematol 1994; 87: 782-8.
23. Kasper CK. In vivo recovery and early half-life of infused factor VIII in haemophilia A. Haemophilia 1995; 1: 14-16.
24. Poon M-C, Aledort LM, Anderle K, Kunschak M, Morfini M, The factor IX study group. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Transfusion 1995; 35: 319-23.
25. Messori A, Longo G, Morfini M, et al. Individualization of Factor VIII dosage. J Clin Hosp Pharm 1984; 9: 95-103.
26. Longo G, Matucci M, Morfini M, Vannini S, Messori A. A calculator program for individualizing Factor VIII dosage. Drug Intell Clin Pharm 1984; 18: 726-30.
27. Carlsson M, Berntorp E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52.
28. Longo G, Matucci M, Messori A, Morfini M, Rossi-Ferrini P. Pharmacokinetics of a new heat-treated concentrate of Factor VIII estimated by model-independent methods. Thromb Research 1986; 42: 471-6.
29. Morfini M, Longo G, Berntorp E, et al. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate. Thromb Research 1993; 71: 175-84.
30. Nilsson IM, Kirkwood TBL, Barrowcliffe TW. In vivo recovery of Factor VIII: a comparison of one-stage and two-stage assay methods. Thrombos Haemostas 1979; 42: 1230-9.
31. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for Factor VIII and Factor IX. Thromb Haemostas 1991; 66: 384-6.
32. Lee ML, Gomperts ED, Kingdon HS. A note on the calculation of recovery for Factor VIII infusions. Thromb Haemostas 1993; 69: 87.
33. Schimpf K, Rothmann P, Schumacher K. Comparison of Factor VIII concentrates in non-bleeding patients. Scand J Haematol 1984; 33 (Suppl. 41): 131-45.
34. Kasper CK, Kim HC, Gomperts ED, et al. In vivo recovery and survival of monoclonal-antibody-purified Factor VIII concentrates. Thromb Haemostas 1991; 66: 730-3.
35. Smit Sibinga CT, Daenen SMGJ, van Imhoff GW, Maas A, Das PC. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate. Thromb Haemostas 1984; 51: 12-5.
36. Dawson NJ, Kemball-Cook G, Barrowcliffe TW. Assay discrepancies with highly purified Factor VIII concentrates. Haemostasis 1989; 19: 131-7.
37. Mikaelsson M, Oswaldsson U, Nilsson IM. Potency and in vivo recovery of high purity Factor VIII concentrates. Thromb Haemostas 1994; 72: 160-1.
38. Messori A, Longo G, Morfini M, et al. Multi-variate analysis of factors governing the pharmacokinetics of exogenous Factor VIII in haemophiliacs. Eur J Clin Pharmacol 1988; 35: 663-8.
39. Brettler DB, Forsberg AD, Levine PH, et al. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 73: 1859-63.
40. Smith KJ, Lusher JM, Cohen AR, Salzman P. Initial clinical experience with a new pasteurized monoclonal antibody purified Factor VIIIC. Semin Hematol 1990, 27, (Suppl.2): 25-9.
41. Mannucci PM, Morfini M. Determination of pharmacokinetics of replacement Factor VIII. Semin Hematol 1990; 27 (Suppl. 2): 8-10.
42. Knevelman A, de Wit HJC, Potstra P, vd Does JA. Development and small-scale production of a severely heated factor VIII concentrate. Vox Sang 1994; 66: 89-95.
43. Heldebrant CM, Gomperts ED, Kasper CK, et al. Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates. Transfusion 1985; 25: 510-15.
44. Menache D. Coagulation factor IX concentrate: Properties and clinical investigation (abstract). Thromb Haemostas 1985; 54: 282.
45. Kim HC, McMillan CW, White GC, Bergman GE, Saidi P. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. Semin Hematol 1990; 27 (Suppl. 2): 30-5.
46. Kasper CK, Boylen AL, Ewing NP, Luck JV, Dietrich SL. Hematologic management of hemophilia A for surgery. J Amer Med Ass 1985; 253: 1279-83.
47. Doughty HA, Coles J, Parmar K, Bullock P, Savidge GF. The successful removal of a bleeding intracranial tumour in a severe haemophiliac using an adjusted dose continuous infusion of monoclonal factor VIII. Blood Coag Fibrinolys 1995; 6: 31-4.
48. Longo G, Messori A, Morfini M, et al. Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. Am J Hematol 1989; 30: 140-9.
49. Aronstam A, McLellan DS, Wassef M, Mbatha PS. Effect of height and weight on the in vivo recovery of transfused factor VIII C. J Clin Pathol 1982; 35: 289-91.
50. White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE, the Mononine Study Group. Variability of in vivo recovery of Factor IX after infusion of monoclonal antibody purified Factor IX concentrates in patients with hemophilia B. Thromb Haemostas 1995; 73: 779-84.
51. Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977; 56: 605-12.
52. Tuddenham EGD, Lane RS, Rotblat F, Johnson AJ, Snape TJ, Middleton S, Kernoff PBA. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 1982; 52: 259-67.
53. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992; 65: 253-9.
54. Morfini M, Mannucci PM, Tenconi PM, et al. Pharmacokinetics of monoclonally-purified and recombinant Factor VIII in patients with severe von Willebrand disease. Thromb Haemostas 1993; 70: 270-2.
55. Duncan B, Lloyd J, Lesnikowski E. Successive Factor VIII doses for a haemophiliac undergoing major surgery calculated on a microcomputer. Thromb Haemostas 1982; 47: 66-8.
56. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
57. Morfini M, Mannucci PM, Longo G, Cinotti S, Messori A. Comparative evaluation of the pharmacokinetics of three monoclonal Factor VIII concentrates. Thromb Research 1991; 61: 285-90.
58. Messori A, Morfini M, Blombäck M, et al. Pharmacokinetics of two pasteurized Factor VIII concentrates by different and multicenter assays of Factor VIII activity. Thromb Research 1992; 65: 699-708.